Pro-Life Advocates Detail Demands for FDA Leadership Amidst Withdrawn Nomination

A prominent pro-life organization outlined its policy expectations for the next Food and Drug Administration leader, emphasizing concerns over abortion medication access, following the recent withdrawal of Heidi Overton's nomination.

November 20, 2026

Pro-Life Advocates Detail Demands for FDA Leadership Amidst Withdrawn Nomination

A prominent pro-life organization expressed its opposition to advancing Heidi Overton's nomination to lead the Food and Drug Administration without specific commitments from the Trump administration regarding abortion drug policy. The White House subsequently withdrew her nomination this week, citing questions about her level of support within the Senate.

Mr. Baptist, a spokesperson for the group, stated that the organization expects any future FDA nominee to commit to discontinuing mail-order access to abortion medications, which were authorized under the Biden administration. Additionally, the group seeks changes in how the agency assesses the safety of these pills.

"Right now, we’re seeing more abortions in this country than before the Supreme Court’s decision overturning Roe v. Wade," Baptist said. "That’s precisely because of what the Biden FDA did to authorize mail-order abortion drugs. We’re seeing upwards of 15,000 abortion drugs and abortions occurring in pro-life states. Those states can’t meaningfully enforce their laws while this nationwide policy is in place."

He continued to elaborate on the implications of the current policy, stating, "Under the Biden-era policy, anybody can obtain these drugs online and receive them through the mail. When I say anybody, we’ve seen news story after news story every week about men and other predators obtaining these drugs to coerce or poison women into taking them against their will. Until that policy changes, no pregnant woman is safe from these drugs. My question to this administration is: How many more women have to be poisoned or coerced with abortion drugs before you take action on this drug?"

Under the Biden administration, the FDA removed the requirement for mifepristone to be dispensed in person. This change allowed the medication to be prescribed without an in-person visit by certified prescribers and distributed through certified pharmacies via mail.

Concerns Over Abortion Drug Access and Safety

Regarding the organization's second primary concern, Baptist asserted that the FDA must conduct a new, thorough study to definitively establish the safety, or lack thereof, of mifepristone.

"The problem is that the study is significantly flawed," he said. "It’s almost designed to fail and not lead to future changes to the drug regimen. We have asked for more robust data because significant information is currently lacking, including transparency into the agency’s methodology and an invitation for outside experts who have studied this drug over the last few decades."

He added that such a call for improved data and transparency should garner bipartisan support. "This is something that should be bipartisan. Everybody should support better data, more transparency and outside experts who can inform an agency that has never conducted such a study before," Baptist emphasized.

Several pro-life organizations and Republican lawmakers have previously urged the Trump administration to complete the FDA’s safety review of mifepristone and consider reintroducing safeguards, with some even advocating for the drug's complete removal from the market.

The FDA has indicated that its review is ongoing, with study results anticipated in December 2026 and a final report expected by March 2027.

The Withdrawn Nomination and Senate Dynamics

The White House withdrew Overton’s nomination to lead the FDA earlier this week, just one day before a scheduled Senate committee vote. President Donald Trump had selected Overton, a physician and White House advisor, in August to succeed Marty Makary, who had stepped down from the position in May.

Kyle Diamantas has been leading the agency in an acting capacity since Makary’s departure.

The White House stated that Overton lacked sufficient votes on Capitol Hill, leading to the withdrawal of her nomination. However, Senator Bill Cassidy, a Republican from Louisiana and chair of the Senate health committee, challenged this assertion, contending that he believed she could have been confirmed.

"The White House abandoned a viable confirmation path for Dr. Overton. The WH said that this was because she did not have the votes to pass. This was odd as I was having productive conversations with members," Cassidy wrote on X. "I believe she would have had the votes to pass out of committee and pass the full Senate."

Baptist stated he was unaware whether the White House's concerns stemmed from pro-life votes or other constituencies. However, he believed Senator Cassidy "was making progress with the administration to secure the commitments we were seeking and asking the Senate to hold the administration accountable for."

Overton's Policy Stance and Future FDA Leadership

Overton previously served as vice chair and chief policy officer at the America First Policy Institute, a conservative think tank, where she expressed criticism of expanded access to abortion pills in a 2023 policy brief.

Senator Cassidy had initially criticized Overton for her support of Trump’s recommendation for changes to the childhood vaccine schedule. However, the senator later indicated he was convinced she was suitable for the role after she committed to "follow the science." Overton had appeared alongside Trump in the Oval Office when the president signed an executive order advocating for changes to childhood vaccine recommendations, including a proposal to administer measles, mumps, and rubella vaccines separately once individual shots become domestically available.

At a September hearing, Cassidy had noted a lack of scientific evidence for Trump’s suggestion that the combined shot could be "quite lethal," warning that such remarks could discourage vaccination.

"Yes, senator, the MMR vaccine is safe and effective," Overton told Cassidy.

When pressed on her actions if Trump were to ask her to disregard the FDA’s safety standards, Overton responded that she would offer the president her best advice and adhere to all legal requirements for reviewing individual products.

Senator Maggie Hassan, a Democrat from New Hampshire, directly questioned Overton on whether Trump's statements were incorrect. Overton reiterated that the vaccine was safe and effective, describing it as the most effective tool available during the measles outbreak. Senator Ed Markey, a Democrat from Massachusetts, questioned her failure to correct Trump during the Oval Office appearance.

"Why should we expect you to stand up to the president as FDA commissioner?" Markey asked.

Baptist expressed a desire for the next FDA commissioner to be an individual who "understands science" and possesses experience in managing an agency.

"The FDA is a very large bureaucracy with multiple constituencies, so understanding how science is conducted and how drugs are approved will be essential to any successful candidate or nominee for the position," he said.

However, Baptist emphasized that the administration does not need to await the appointment of an FDA nominee to implement the abortion pill policy changes his group seeks.

"The good news is that it doesn’t have to be the nominee who makes these commitments. The administration can do it because it has admitted that it can take these actions immediately using its own authority," he argued. "That power is within the administration’s possession. It’s a matter of political will, not legal ability."

Baptist further added, "With regard to fixing the study, I think they can make those changes now. They don’t need to wait for a confirmation, especially when they’re saying they’re going to finish the study in December of this year. We might not have an FDA commissioner at that point, or even a nominee. So they need to fix it immediately and course-correct the study before it’s fatally flawed and completed next year."

pro-life policyFDA nominationabortion drugsmifepristoneTrump administrationHeidi Overtonmail-order abortion pillsdrug safety studies

More Top Stories